Shopping Cart 0
Cart Subtotal
AED 0

Global Blau Syndrome Market - Industry Trends and Forecast to 2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 17616

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 25690

Details

Global Blau syndrome market is projected to register a healthy CAGR of 11.9% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Global Blau Syndrome Market, By Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey and Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and Rest of Middle East and Africa)-Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of global Blau syndrome market are:

Emergence of drugs used to treat symptoms associated with Blau syndrome

Advancement in health care industry

Market Players:

The key market players for global Blau syndrome market are listed below:

Novartis AG

Pfizer Inc.

AbbVie Inc.

Amgen Inc.

Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)

Mylan N.V.

Hikma Pharmaceuticals PLC

Teva Pharmaceutical U.S.A Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)

Fulgent Genetics Inc.

Invitae Corporation

Swedish Orphan Biovitrum AB

Alkem Labs

Accord Healthcare

F. Hoffmann-La Roche Ltd

Zydus Pharmaceuticals (USA) Inc. (a subsidiary of Zydus cadila)

Amneal Pharmaceuticals LLC

Salix Pharmaceuticals (a subsidiary of Bausch Health Companies Inc.)

Centogene AG

Oncodesign

READ MORE

Table Of Content

Scope

TABLE OF CONTENTS

1 INTRODUCTION 58

1.1 OBJECTIVES OF THE STUDY 58

1.2 MARKET DEFINITION 58

1.3 OVERVIEW OF GLOBAL BLAU SYNDROME MARKET 58

1.4 LIMITATIONS 60

1.5 MARKETS COVERED 60

2 MARKET SEGMENTATION 64

2.1 MARKETS COVERED 64

2.2 GEOGRAPHICAL SCOPE 65

2.3 YEARS CONSIDERED FOR THE STUDY 66

2.4 CURRENCY AND PRICING 66

2.5 DBMR TRIPOD DATA VALIDATION MODEL 67

2.6 MULTIVARIATE MODELLING 70

2.7 THERAPEUTIC AREAS OF BLAU SYNDROME LIFELINE CURVE 70

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 71

2.9 DBMR MARKET POSITION GRID 72

2.10 VENDOR SHARE ANALYSIS 73

2.11 SECONDARY SOURCES 74

2.12 ASSUMPTIONS 74

3 EXECUTIVE SUMMARY 75

4 GLOBAL BLAU SYNDROME MARKET: REGULATIONS 80

5 MARKET OVERVIEW 82

5.1 DRIVERS 84

5.1.1 HIGH ADOPTION OF BIOLOGICAL THERAPIES 84

5.1.2 EMERGENCE OF DRUGS USED TO TREAT SYMPTOMS ASSOCIATED WITH BLAU SYNDROME 84

5.1.3 HIGH DEMAND OF DISEASE SPECIFIC TREATMENT 85

5.1.4 ADVANCEMENTS IN HEALTH CARE INDUSTRY 85

5.1.5 AVAILABILITY OF OFF LABEL DRUGS 86

5.2 RESTRAINTS 87

5.2.1 UNAVAILABILITY AND UNAFFORDABILITY OF EFFECTIVE TREATMENT 87

5.2.2 POOR DIAGNOSIS RATE IN SOME DEVELOPING COUNTRIES 87

5.2.3 LARGE NUMBER OF SIDE EFFECTS OF AVAILABLE DRUGS 87

5.3 OPPORTUNITIES 88

5.3.1 RISING DISPOSABLE INCOME 88

5.3.2 RISING STRATEGIC INITIATIVES BY PHARMACEUTICAL COMPANIES 88

5.3.3 EMERGING MARKETS 89

5.3.4 INCREASING RESEARCH AND DEVELOPMENT 89

5.4 CHALLENGES 90

5.4.1 LACK OF APPROVED DRUGS 90

5.4.2 HIGH COST ASSOCIATED WITH SYNDROME DIAGONSIS 90

5.4.3 LACK OF SKILLED RESOURCE FOR PERFORMING GENETIC TESTS 90

6 IMPACT OF COVID-19 PANDEMIC ON THE GLOBAL BLAU SYNDROME MARKET 91

6.1 PRICE IMPACT 91

6.2 IMPACT ON DEMAND 91

6.3 IMPACT ON SUPPLY CHAIN 92

6.4 STRATEGIC DECISIONS FOR MANUFACTURERS 92

6.5 CONCLUSION 93

7 GLOBAL BLAU SYNDROME MARKET, BY TYPE 94

7.1 OVERVIEW 95

7.2 TREATMENT 98

7.2.1 CORTICOSTEROIDS 99

7.2.1.1 PREDNISOLONE 99

7.2.1.2 COMBINATION CORTICOSTEROIDS 99

7.2.1.3 NAPROXEN 99

7.2.1.4 OTHERS 99

7.2.2 IMMUNOSUPPRESSANTS 99

7.2.2.1 METHOTREXATE 100

7.2.2.2 MYCOPHENOLATE MOFETIL 100

7.2.2.3 AZATHIOPRINE 100

7.2.2.4 OTHERS 100

7.2.3 TNF-? INHIBITORS 100

7.2.3.1 INFLIXIMAB 101

7.2.3.2 ADALIMUMAB 101

7.2.3.3 ETANERCEPT 101

7.2.3.4 OTHERS 101

7.2.4 OPTHALMIC MEDICATION 101

7.2.4.1 PREDNISOLONE ACETATE 101

7.2.4.2 TROPICAMIDE 101

7.2.4.3 OTHERS 101

7.2.5 INTERLEUKIN RECEPTOR 102

7.2.5.1 ANAKINRA 102

7.2.5.2 CANAKINUMAB 102

7.2.5.3 OTHERS 102

7.2.6 OTHERS 102

7.3 DIAGNOSIS 102

7.3.1 SCREENING 103

7.3.1.1 LAB TEST 104

7.3.1.1.1 BLOOD TEST 104

7.3.1.1.2 SALIVA TEST 104

7.3.1.1.3 OTHERS 104

7.3.1.2 IMAGING TEST 104

7.3.1.2.1 CT SCANS 104

7.3.1.2.2 ULTRASOUNDS 105

7.3.1.2.3 OTHERS 105

7.3.2 CONFIRMATORY TEST 105

7.3.2.1 SKIN BIOPSY 105

7.3.2.2 GENETIC TEST 105

7.3.2.3 OTHERS 105

8 GLOBAL BLAU SYNDROME MARKET, BY THERAPEUTIC AREAS 106

8.1 OVERVIEW 107

8.2 SKIN RASH 110

8.3 INFLAMMATION 110

8.3.1 GRANULOMATOUS DERMATITIS 112

8.3.2 SYNOVITIS 112

8.3.3 UVEITIS 112

8.3.4 GRANULOMATOUS ARTHRITIS 112

8.3.5 CHRONIC ARTHRITIS 112

8.3.6 OTHERS 112

9 GLOBAL BLAU SYNDROME MARKET, BY ROUTE OF ADMINISTRATION 113

9.1 OVERVIEW 114

9.2 ORAL 117

9.2.1 TABLET 118

9.2.2 CAPSULE 118

9.2.3 OTHERS 118

9.3 PARENTERAL 118

9.3.1 INTRAVENOUS 119

9.3.2 SUBCUTANEOUS 119

9.3.3 OTHERS 119

9.4 TOPICAL 119

9.4.1 OINTMENT 120

9.4.2 SOLUTION 120

9.4.3 OTHERS 120

9.5 OTHERS 120

10 GLOBAL BLAU SYNDROME MARKET, BY END USER 122

10.1 OVERVIEW 123

10.2 HOSPITALS 125

10.3 DIAGNOSTICS CENTERS 126

10.4 CLINICS 127

10.5 HOME HEALTHCARE 127

10.6 OTHERS 128

11 GLOBAL BLAU SYNDROME MARKET, BY DISTRIBUTION CHANNEL 129

11.1 OVERVIEW 130

11.2 HOSPITAL PHARMACY 132

11.3 RETAIL PHARMACY 133

11.4 ONLINE PHARMACY 134

11.5 DIRECT TENDER 135

11.6 OTHERS 136

12 GLOBAL BLAU SYNDROME MARKET, BY GEOGRAPHY 137

12.1 OVERVIEW 138

12.2 NORTH AMERICA 143

12.2.1 U.S. 152

12.2.2 CANADA 157

12.2.3 MEXICO 162

12.3 EUROPE 167

12.3.1 GERMANY 176

12.3.2 FRANCE 181

12.3.3 U.K. 186

12.3.4 ITALY 191

12.3.5 NETHERLANDS 196

12.3.6 SPAIN 202

12.3.7 RUSSIA 207

12.3.8 SWITZERLAND 212

12.3.9 TURKEY 218

12.3.10 AUSTRIA 223

12.3.11 NORWAY 228

12.3.12 HUNGARY 233

12.3.13 LITHUANIA 238

12.3.14 IRELAND 243

12.3.15 POLAND 248

12.3.16 REST OF EUROPE 253

12.4 ASIA PACIFIC 254

12.4.1 JAPAN 263

12.4.2 CHINA 268

12.4.3 AUSTRAILA 273

12.4.4 SOUTH KOREA 279

12.4.5 INDIA 285

12.4.6 SINGAPORE 290

12.4.7 MALAYSIA 296

12.4.8 THAILAND 301

12.4.9 INDONESIA 306

12.4.10 PHILIPPINES 312

12.4.11 VIETNAM 318

12.4.12 REST OF ASIA-PACIFIC 323

12.5 SOUTH AMERICA 324

12.5.1 BRAZIL 333

12.5.2 ARGENTINA 338

12.5.3 PERU 344

12.5.4 REST OF SOUTH AMERICA 349

12.6 MIDDLE EAST & AFRICA 350

12.6.1 SAUDI ARABIA 359

12.6.2 SOUTH AFRICA 365

12.6.3 UAE 371

12.6.4 ISRAEL 376

12.6.5 KUWAIT 381

12.6.6 EGYPT 386

12.6.7 REST OF MIDDLE EAST & AFRICA 391

13 GLOBAL BLAU SYNDROME MARKET, COMPANY LANDSCAPE 392

13.1 COMPANY SHARE ANALYSIS: GLOBAL 392

13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 393

13.3 COMPANY SHARE ANALYSIS: EUROPE 394

13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 395

14 SWOT 396

15 COMPANY PROFILES 397

15.1 NOVARTIS AG 397

15.1.1 COMPANY SNAPSHOT 397

15.1.2 REVENUE ANALYSIS 397

15.1.3 COMPANY SHARE ANALYSIS 398

15.1.4 PRODUCT PORTFOLIO 398

15.1.5 RECENT DEVELOPMENTS 398

15.2 AMGEN INC. 399

15.2.1 COMPANY SNAPSHOT 399

15.2.2 REVENUE ANALYSIS 399

15.2.3 COMPANY SHARE ANALYSIS 400

15.2.4 PRODUCT PORTFOLIO 400

15.2.5 RECENT DEVELOPMENTS 400

15.3 PFIZER INC. 401

15.3.1 COMPANY SNAPSHOT 401

15.3.2 REVENUE ANALYSIS 401

15.3.3 COMPANY SHARE ANALYSIS 402

15.3.4 PRODUCT PORTFOLIO 402

15.3.5 RECENT DEVELOPMENTS 402

15.4 JANSSEN PHARMACEUTICALS, INC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 403

15.4.1 COMPANY SNAPSHOT 403

15.4.2 REVENUE ANALYSIS 403

15.4.3 COMPANY SHARE ANALYIS 404

15.4.4 PRODUCT PORTFOLIO 404

15.4.5 RECENT DEVELOPMENT 404

15.5 ABBVIE INC. 405

15.5.1 COMPANY SNAPSHOT 405

15.5.2 REVENUE ANALYSIS 405

15.5.3 COMPANY SHARE ANALYSIS 406

15.5.4 PRODUCT PORTFOLIO 406

15.5.5 RECENT DEVELOPMENTS 406

15.6 ACCORD HEALTHCARE 408

15.6.1 COMPANY SNAPSHOT 408

15.6.2 PRODUCT PORTFOLIO 408

15.6.3 RECENT DEVELOPMENTS 408

15.7 ALKEM LABS 409

15.7.1 COMPANY SNAPSHOT 409

15.7.2 REVENUE ANALYSIS 409

15.7.3 PRODUCT PORTFOLIO 410

15.7.4 RECENT DEVELOPMENT 410

15.8 AMNEAL PHARMACEUTICALS LLC 411

15.8.1 COMPANY SNAPSHOT 411

15.8.2 REVENUE ANALYSIS 411

15.8.3 PRODUCT PORTFOLIO 411

15.8.4 RECENT DEVELOPMENTS 412

15.9 CENTOGENE N.V. 413

15.9.1 COMPANY SNAPSHOT 413

15.9.2 REVENUE ANALYSIS 413

15.9.3 PRODUCT PORTFOLIO 413

15.9.4 RECENT DEVELOPMENTS 414

15.10 F. HOFFMANN-LA ROCHE LTD 415

15.10.1 COMPANY SNAPSHOT 415

15.10.2 REVENUE ANALYSIS 415

15.10.3 PRODUCT PORTFOLIO 416

15.10.4 RECENT DEVELOPMENT 416

15.11 FULGENT GENETICS 417

15.11.1 COMPANY SNAPSHOT 417

15.11.2 REVENUE ANALYSIS 417

15.11.3 PRODUCT PORTFOLIO 417

15.11.4 RECENT DEVELOPMENT 418

15.12 HIKMA PHARMACEUTICALS PLC 419

15.12.1 COMPANY SNAPSHOT 419

15.12.2 REVENUE ANALYSIS 419

15.12.3 PRODUCT PORTFOLIO 420

15.12.4 RECENT DEVELOPMENTS 420

15.13 INVITAE CORPORATION 421

15.13.1 COMPANY SNAPSHOT 421

15.13.2 REVENUE ANALYSIS 421

15.13.3 PRODUCT PORTFOLIO 422

15.13.4 RECENT DEVELOPMENTS 422

15.14 MYLAN N.V. 423

15.14.1 COMPANY SNAPSHOT 423

15.14.2 REVENUE ANALYSIS 423

15.14.3 PRODUCT PORTFOLIO 424

15.14.4 RECENT DEVELOPMENTS 424

15.15 ONCODESIGN 425

15.15.1 COMPANY SNAPSHOT 425

15.15.2 REVENUE ANALYSIS 425

15.15.3 PRODUCT PORTFOLIO 425

15.15.4 RECENT DEVELOPMENT 426

15.16 SALIX PHARMACEUTICALS (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.) 427

15.16.1 COMPANY SNAPSHOT 427

15.16.2 REVENUE ANALYSIS 427

15.16.3 PRODUCT PORTFOLIO 428

15.16.4 RECENT DEVELOPMENT 428

15.17 SWEDISH ORPHAN BIOVITRUM AB (PUBL) 429

15.17.1 COMPANY SNAPSHOT 429

15.17.2 REVENUE ANALYSIS 429

15.17.3 PRODUCT PORTFOLIO 429

15.17.4 RECENT DEVELOPMENTS 430

15.18 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 431

15.18.1 COMPANY SNAPSHOT 431

15.18.2 REVENUE ANALYSIS 431

15.18.3 PRODUCT PORTFOLIO 432

15.18.4 RECENT DEVELOPMENTS 432

15.19 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA) 433

15.19.1 COMPANY SNAPSHOT 433

15.19.2 REVENUE ANALYSIS 433

15.19.3 PRODUCT PORTFOLIO 433

15.19.4 RECENT DEVELOPMENTS 434

16 QUESTIONNAIRE 435

17 RELATED REPORTS 438


List Of Figure

LIST OF FIGURES

FIGURE 1 GLOBAL BLAU SYNDROME MARKET: SEGMENTATION 64

FIGURE 2 GLOBAL BLAU SYNDROME MARKET : DATA TRIANGULATION 67

FIGURE 3 GLOBAL BLAU SYNDROME MARKET: DROC ANALYSIS 68

FIGURE 4 GLOBAL BLAU SYNDROME MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 69

FIGURE 5 GLOBAL BLAU SYNDROME MARKET: COMPANY RESEARCH ANALYSIS 69

FIGURE 6 GLOBAL BLAU SYNDROME MARKET: MULTIVARIATE MODELLING 70

FIGURE 7 GLOBAL BLAU SYNDROME MARKET: INTERVIEW DEMOGRAPHICS 71

FIGURE 8 GLOBAL BLAU SYNDROME MARKET: DBMR MARKET POSITION GRID 72

FIGURE 9 GLOBAL BLAU SYNDROME MARKET: VENDOR SHARE ANALYSIS 73

FIGURE 10 GLOBAL BLAU SYNDROME MARKET: SEGMENTATION 76

FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 77

FIGURE 12 HIGH ADOPTION OF BIOLOGICAL THERAPIES AND HIGH DEMAND OF DISEASE SPECIFIC TREATMENT IS DRIVING THE GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 78

FIGURE 13 TREATMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BLAU SYNDROME MARKET IN 2020 & 2027 78

FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET IN GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 79

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF GLOBAL BLAU SYNDROME MARKET 83

FIGURE 16 GLOBAL BLAU SYNDROME MARKET: BY TYPE, 2019 95

FIGURE 17 GLOBAL BLAU SYNDROME MARKET: BY TYPE, 2019-2027 (USD THOUSAND) 96

FIGURE 18 GLOBAL BLAU SYNDROME MARKET: BY TYPE, CAGR (2020-2027) 96

FIGURE 19 GLOBAL BLAU SYNDROME MARKET: BY TYPE, LIFELINE CURVE 97

FIGURE 20 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019 107

FIGURE 21 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019-2027 (USD THOUSAND) 108

FIGURE 22 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027) 108

FIGURE 23 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE 109

FIGURE 24 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019 114

FIGURE 25 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD THOUSAND) 115

FIGURE 26 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027) 115

FIGURE 27 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 116

FIGURE 28 GLOBAL BLAU SYNDROME MARKET: BY END USER, 2019 123

FIGURE 29 GLOBAL BLAU SYNDROME MARKET: BY END USER, 2019-2027 (USD THOUSAND) 124

FIGURE 30 GLOBAL BLAU SYNDROME MARKET: BY END USER, CAGR (2020-2027) 124

FIGURE 31 GLOBAL BLAU SYNDROME MARKET: BY END USER, LIFELINE CURVE 125

FIGURE 32 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019 130

FIGURE 33 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND) 131

FIGURE 34 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 131

FIGURE 35 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 132

FIGURE 36 GLOBAL BLAU SYNDROME MARKET: SNAPSHOT (2019) 139

FIGURE 37 GLOBAL BLAU SYNDROME MARKET: BY REGION (2019) 140

FIGURE 38 GLOBAL BLAU SYNDROME MARKET: BY REGION (2020 & 2027) 140

FIGURE 39 GLOBAL BLAU SYNDROME MARKET: BY REGION (2019 & 2027) 141

FIGURE 40 GLOBAL BLAU SYNDROME MARKET: BY TYPE (2020-2027) 141

FIGURE 41 NORTH AMERICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 143

FIGURE 42 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 144

FIGURE 43 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 144

FIGURE 44 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 145

FIGURE 45 NORTH AMERICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 145

FIGURE 46 EUROPE BLAU SYNDROME MARKET: SNAPSHOT (2019) 167

FIGURE 47 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019) 168

FIGURE 48 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 168

FIGURE 49 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 169

FIGURE 50 EUROPE BLAU SYNDROME MARKET: BY TYPE (2020-2027) 169

FIGURE 51 ASIA PACIFIC BLAU SYNDROME MARKET: SNAPSHOT (2019) 254

FIGURE 52 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2019) 255

FIGURE 53 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 255

FIGURE 54 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 256

FIGURE 55 ASIA PACIFIC BLAU SYNDROME MARKET: BY TYPE (2020-2027) 256

FIGURE 56 SOUTH AMERICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 324

FIGURE 57 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 325

FIGURE 58 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 325

FIGURE 59 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 326

FIGURE 60 SOUTH AMERICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 326

FIGURE 61 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 350

FIGURE 62 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 351

FIGURE 63 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 351

FIGURE 64 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 352

FIGURE 65 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 352

FIGURE 66 GLOBAL BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 392

FIGURE 67 NORTH AMERICA BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 393

FIGURE 68 EUROPE BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 394

FIGURE 69 ASIA-PACIFIC BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 395

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Novartis AG

Pfizer Inc.

AbbVie Inc.

Amgen Inc.

Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)

Mylan N.V.

Hikma Pharmaceuticals PLC

Teva Pharmaceutical U.S.A Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)

Fulgent Genetics Inc.

Invitae Corporation

Swedish Orphan Biovitrum AB

Alkem Labs

Accord Healthcare

F. Hoffmann-La Roche Ltd

Zydus Pharmaceuticals (USA) Inc. (a subsidiary of Zydus cadila)

Amneal Pharmaceuticals LLC

Salix Pharmaceuticals (a subsidiary of Bausch Health Companies Inc.)

Centogene AG

Oncodesign

Company Profile

Company Profile Title

Global Blau syndrome market is projected to register a healthy CAGR of 11.9% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Global Blau Syndrome Market, By Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey and Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and Rest of Middle East and Africa)-Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of global Blau syndrome market are:

Emergence of drugs used to treat symptoms associated with Blau syndrome

Advancement in health care industry

Market Players:

The key market players for global Blau syndrome market are listed below:

Novartis AG

Pfizer Inc.

AbbVie Inc.

Amgen Inc.

Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)

Mylan N.V.

Hikma Pharmaceuticals PLC

Teva Pharmaceutical U.S.A Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)

Fulgent Genetics Inc.

Invitae Corporation

Swedish Orphan Biovitrum AB

Alkem Labs

Accord Healthcare

F. Hoffmann-La Roche Ltd

Zydus Pharmaceuticals (USA) Inc. (a subsidiary of Zydus cadila)

Amneal Pharmaceuticals LLC

Salix Pharmaceuticals (a subsidiary of Bausch Health Companies Inc.)

Centogene AG

Oncodesign

READ MORE

Scope

TABLE OF CONTENTS

1 INTRODUCTION 58

1.1 OBJECTIVES OF THE STUDY 58

1.2 MARKET DEFINITION 58

1.3 OVERVIEW OF GLOBAL BLAU SYNDROME MARKET 58

1.4 LIMITATIONS 60

1.5 MARKETS COVERED 60

2 MARKET SEGMENTATION 64

2.1 MARKETS COVERED 64

2.2 GEOGRAPHICAL SCOPE 65

2.3 YEARS CONSIDERED FOR THE STUDY 66

2.4 CURRENCY AND PRICING 66

2.5 DBMR TRIPOD DATA VALIDATION MODEL 67

2.6 MULTIVARIATE MODELLING 70

2.7 THERAPEUTIC AREAS OF BLAU SYNDROME LIFELINE CURVE 70

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 71

2.9 DBMR MARKET POSITION GRID 72

2.10 VENDOR SHARE ANALYSIS 73

2.11 SECONDARY SOURCES 74

2.12 ASSUMPTIONS 74

3 EXECUTIVE SUMMARY 75

4 GLOBAL BLAU SYNDROME MARKET: REGULATIONS 80

5 MARKET OVERVIEW 82

5.1 DRIVERS 84

5.1.1 HIGH ADOPTION OF BIOLOGICAL THERAPIES 84

5.1.2 EMERGENCE OF DRUGS USED TO TREAT SYMPTOMS ASSOCIATED WITH BLAU SYNDROME 84

5.1.3 HIGH DEMAND OF DISEASE SPECIFIC TREATMENT 85

5.1.4 ADVANCEMENTS IN HEALTH CARE INDUSTRY 85

5.1.5 AVAILABILITY OF OFF LABEL DRUGS 86

5.2 RESTRAINTS 87

5.2.1 UNAVAILABILITY AND UNAFFORDABILITY OF EFFECTIVE TREATMENT 87

5.2.2 POOR DIAGNOSIS RATE IN SOME DEVELOPING COUNTRIES 87

5.2.3 LARGE NUMBER OF SIDE EFFECTS OF AVAILABLE DRUGS 87

5.3 OPPORTUNITIES 88

5.3.1 RISING DISPOSABLE INCOME 88

5.3.2 RISING STRATEGIC INITIATIVES BY PHARMACEUTICAL COMPANIES 88

5.3.3 EMERGING MARKETS 89

5.3.4 INCREASING RESEARCH AND DEVELOPMENT 89

5.4 CHALLENGES 90

5.4.1 LACK OF APPROVED DRUGS 90

5.4.2 HIGH COST ASSOCIATED WITH SYNDROME DIAGONSIS 90

5.4.3 LACK OF SKILLED RESOURCE FOR PERFORMING GENETIC TESTS 90

6 IMPACT OF COVID-19 PANDEMIC ON THE GLOBAL BLAU SYNDROME MARKET 91

6.1 PRICE IMPACT 91

6.2 IMPACT ON DEMAND 91

6.3 IMPACT ON SUPPLY CHAIN 92

6.4 STRATEGIC DECISIONS FOR MANUFACTURERS 92

6.5 CONCLUSION 93

7 GLOBAL BLAU SYNDROME MARKET, BY TYPE 94

7.1 OVERVIEW 95

7.2 TREATMENT 98

7.2.1 CORTICOSTEROIDS 99

7.2.1.1 PREDNISOLONE 99

7.2.1.2 COMBINATION CORTICOSTEROIDS 99

7.2.1.3 NAPROXEN 99

7.2.1.4 OTHERS 99

7.2.2 IMMUNOSUPPRESSANTS 99

7.2.2.1 METHOTREXATE 100

7.2.2.2 MYCOPHENOLATE MOFETIL 100

7.2.2.3 AZATHIOPRINE 100

7.2.2.4 OTHERS 100

7.2.3 TNF-? INHIBITORS 100

7.2.3.1 INFLIXIMAB 101

7.2.3.2 ADALIMUMAB 101

7.2.3.3 ETANERCEPT 101

7.2.3.4 OTHERS 101

7.2.4 OPTHALMIC MEDICATION 101

7.2.4.1 PREDNISOLONE ACETATE 101

7.2.4.2 TROPICAMIDE 101

7.2.4.3 OTHERS 101

7.2.5 INTERLEUKIN RECEPTOR 102

7.2.5.1 ANAKINRA 102

7.2.5.2 CANAKINUMAB 102

7.2.5.3 OTHERS 102

7.2.6 OTHERS 102

7.3 DIAGNOSIS 102

7.3.1 SCREENING 103

7.3.1.1 LAB TEST 104

7.3.1.1.1 BLOOD TEST 104

7.3.1.1.2 SALIVA TEST 104

7.3.1.1.3 OTHERS 104

7.3.1.2 IMAGING TEST 104

7.3.1.2.1 CT SCANS 104

7.3.1.2.2 ULTRASOUNDS 105

7.3.1.2.3 OTHERS 105

7.3.2 CONFIRMATORY TEST 105

7.3.2.1 SKIN BIOPSY 105

7.3.2.2 GENETIC TEST 105

7.3.2.3 OTHERS 105

8 GLOBAL BLAU SYNDROME MARKET, BY THERAPEUTIC AREAS 106

8.1 OVERVIEW 107

8.2 SKIN RASH 110

8.3 INFLAMMATION 110

8.3.1 GRANULOMATOUS DERMATITIS 112

8.3.2 SYNOVITIS 112

8.3.3 UVEITIS 112

8.3.4 GRANULOMATOUS ARTHRITIS 112

8.3.5 CHRONIC ARTHRITIS 112

8.3.6 OTHERS 112

9 GLOBAL BLAU SYNDROME MARKET, BY ROUTE OF ADMINISTRATION 113

9.1 OVERVIEW 114

9.2 ORAL 117

9.2.1 TABLET 118

9.2.2 CAPSULE 118

9.2.3 OTHERS 118

9.3 PARENTERAL 118

9.3.1 INTRAVENOUS 119

9.3.2 SUBCUTANEOUS 119

9.3.3 OTHERS 119

9.4 TOPICAL 119

9.4.1 OINTMENT 120

9.4.2 SOLUTION 120

9.4.3 OTHERS 120

9.5 OTHERS 120

10 GLOBAL BLAU SYNDROME MARKET, BY END USER 122

10.1 OVERVIEW 123

10.2 HOSPITALS 125

10.3 DIAGNOSTICS CENTERS 126

10.4 CLINICS 127

10.5 HOME HEALTHCARE 127

10.6 OTHERS 128

11 GLOBAL BLAU SYNDROME MARKET, BY DISTRIBUTION CHANNEL 129

11.1 OVERVIEW 130

11.2 HOSPITAL PHARMACY 132

11.3 RETAIL PHARMACY 133

11.4 ONLINE PHARMACY 134

11.5 DIRECT TENDER 135

11.6 OTHERS 136

12 GLOBAL BLAU SYNDROME MARKET, BY GEOGRAPHY 137

12.1 OVERVIEW 138

12.2 NORTH AMERICA 143

12.2.1 U.S. 152

12.2.2 CANADA 157

12.2.3 MEXICO 162

12.3 EUROPE 167

12.3.1 GERMANY 176

12.3.2 FRANCE 181

12.3.3 U.K. 186

12.3.4 ITALY 191

12.3.5 NETHERLANDS 196

12.3.6 SPAIN 202

12.3.7 RUSSIA 207

12.3.8 SWITZERLAND 212

12.3.9 TURKEY 218

12.3.10 AUSTRIA 223

12.3.11 NORWAY 228

12.3.12 HUNGARY 233

12.3.13 LITHUANIA 238

12.3.14 IRELAND 243

12.3.15 POLAND 248

12.3.16 REST OF EUROPE 253

12.4 ASIA PACIFIC 254

12.4.1 JAPAN 263

12.4.2 CHINA 268

12.4.3 AUSTRAILA 273

12.4.4 SOUTH KOREA 279

12.4.5 INDIA 285

12.4.6 SINGAPORE 290

12.4.7 MALAYSIA 296

12.4.8 THAILAND 301

12.4.9 INDONESIA 306

12.4.10 PHILIPPINES 312

12.4.11 VIETNAM 318

12.4.12 REST OF ASIA-PACIFIC 323

12.5 SOUTH AMERICA 324

12.5.1 BRAZIL 333

12.5.2 ARGENTINA 338

12.5.3 PERU 344

12.5.4 REST OF SOUTH AMERICA 349

12.6 MIDDLE EAST & AFRICA 350

12.6.1 SAUDI ARABIA 359

12.6.2 SOUTH AFRICA 365

12.6.3 UAE 371

12.6.4 ISRAEL 376

12.6.5 KUWAIT 381

12.6.6 EGYPT 386

12.6.7 REST OF MIDDLE EAST & AFRICA 391

13 GLOBAL BLAU SYNDROME MARKET, COMPANY LANDSCAPE 392

13.1 COMPANY SHARE ANALYSIS: GLOBAL 392

13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 393

13.3 COMPANY SHARE ANALYSIS: EUROPE 394

13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 395

14 SWOT 396

15 COMPANY PROFILES 397

15.1 NOVARTIS AG 397

15.1.1 COMPANY SNAPSHOT 397

15.1.2 REVENUE ANALYSIS 397

15.1.3 COMPANY SHARE ANALYSIS 398

15.1.4 PRODUCT PORTFOLIO 398

15.1.5 RECENT DEVELOPMENTS 398

15.2 AMGEN INC. 399

15.2.1 COMPANY SNAPSHOT 399

15.2.2 REVENUE ANALYSIS 399

15.2.3 COMPANY SHARE ANALYSIS 400

15.2.4 PRODUCT PORTFOLIO 400

15.2.5 RECENT DEVELOPMENTS 400

15.3 PFIZER INC. 401

15.3.1 COMPANY SNAPSHOT 401

15.3.2 REVENUE ANALYSIS 401

15.3.3 COMPANY SHARE ANALYSIS 402

15.3.4 PRODUCT PORTFOLIO 402

15.3.5 RECENT DEVELOPMENTS 402

15.4 JANSSEN PHARMACEUTICALS, INC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 403

15.4.1 COMPANY SNAPSHOT 403

15.4.2 REVENUE ANALYSIS 403

15.4.3 COMPANY SHARE ANALYIS 404

15.4.4 PRODUCT PORTFOLIO 404

15.4.5 RECENT DEVELOPMENT 404

15.5 ABBVIE INC. 405

15.5.1 COMPANY SNAPSHOT 405

15.5.2 REVENUE ANALYSIS 405

15.5.3 COMPANY SHARE ANALYSIS 406

15.5.4 PRODUCT PORTFOLIO 406

15.5.5 RECENT DEVELOPMENTS 406

15.6 ACCORD HEALTHCARE 408

15.6.1 COMPANY SNAPSHOT 408

15.6.2 PRODUCT PORTFOLIO 408

15.6.3 RECENT DEVELOPMENTS 408

15.7 ALKEM LABS 409

15.7.1 COMPANY SNAPSHOT 409

15.7.2 REVENUE ANALYSIS 409

15.7.3 PRODUCT PORTFOLIO 410

15.7.4 RECENT DEVELOPMENT 410

15.8 AMNEAL PHARMACEUTICALS LLC 411

15.8.1 COMPANY SNAPSHOT 411

15.8.2 REVENUE ANALYSIS 411

15.8.3 PRODUCT PORTFOLIO 411

15.8.4 RECENT DEVELOPMENTS 412

15.9 CENTOGENE N.V. 413

15.9.1 COMPANY SNAPSHOT 413

15.9.2 REVENUE ANALYSIS 413

15.9.3 PRODUCT PORTFOLIO 413

15.9.4 RECENT DEVELOPMENTS 414

15.10 F. HOFFMANN-LA ROCHE LTD 415

15.10.1 COMPANY SNAPSHOT 415

15.10.2 REVENUE ANALYSIS 415

15.10.3 PRODUCT PORTFOLIO 416

15.10.4 RECENT DEVELOPMENT 416

15.11 FULGENT GENETICS 417

15.11.1 COMPANY SNAPSHOT 417

15.11.2 REVENUE ANALYSIS 417

15.11.3 PRODUCT PORTFOLIO 417

15.11.4 RECENT DEVELOPMENT 418

15.12 HIKMA PHARMACEUTICALS PLC 419

15.12.1 COMPANY SNAPSHOT 419

15.12.2 REVENUE ANALYSIS 419

15.12.3 PRODUCT PORTFOLIO 420

15.12.4 RECENT DEVELOPMENTS 420

15.13 INVITAE CORPORATION 421

15.13.1 COMPANY SNAPSHOT 421

15.13.2 REVENUE ANALYSIS 421

15.13.3 PRODUCT PORTFOLIO 422

15.13.4 RECENT DEVELOPMENTS 422

15.14 MYLAN N.V. 423

15.14.1 COMPANY SNAPSHOT 423

15.14.2 REVENUE ANALYSIS 423

15.14.3 PRODUCT PORTFOLIO 424

15.14.4 RECENT DEVELOPMENTS 424

15.15 ONCODESIGN 425

15.15.1 COMPANY SNAPSHOT 425

15.15.2 REVENUE ANALYSIS 425

15.15.3 PRODUCT PORTFOLIO 425

15.15.4 RECENT DEVELOPMENT 426

15.16 SALIX PHARMACEUTICALS (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.) 427

15.16.1 COMPANY SNAPSHOT 427

15.16.2 REVENUE ANALYSIS 427

15.16.3 PRODUCT PORTFOLIO 428

15.16.4 RECENT DEVELOPMENT 428

15.17 SWEDISH ORPHAN BIOVITRUM AB (PUBL) 429

15.17.1 COMPANY SNAPSHOT 429

15.17.2 REVENUE ANALYSIS 429

15.17.3 PRODUCT PORTFOLIO 429

15.17.4 RECENT DEVELOPMENTS 430

15.18 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 431

15.18.1 COMPANY SNAPSHOT 431

15.18.2 REVENUE ANALYSIS 431

15.18.3 PRODUCT PORTFOLIO 432

15.18.4 RECENT DEVELOPMENTS 432

15.19 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA) 433

15.19.1 COMPANY SNAPSHOT 433

15.19.2 REVENUE ANALYSIS 433

15.19.3 PRODUCT PORTFOLIO 433

15.19.4 RECENT DEVELOPMENTS 434

16 QUESTIONNAIRE 435

17 RELATED REPORTS 438


List Of Figure

LIST OF FIGURES

FIGURE 1 GLOBAL BLAU SYNDROME MARKET: SEGMENTATION 64

FIGURE 2 GLOBAL BLAU SYNDROME MARKET : DATA TRIANGULATION 67

FIGURE 3 GLOBAL BLAU SYNDROME MARKET: DROC ANALYSIS 68

FIGURE 4 GLOBAL BLAU SYNDROME MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 69

FIGURE 5 GLOBAL BLAU SYNDROME MARKET: COMPANY RESEARCH ANALYSIS 69

FIGURE 6 GLOBAL BLAU SYNDROME MARKET: MULTIVARIATE MODELLING 70

FIGURE 7 GLOBAL BLAU SYNDROME MARKET: INTERVIEW DEMOGRAPHICS 71

FIGURE 8 GLOBAL BLAU SYNDROME MARKET: DBMR MARKET POSITION GRID 72

FIGURE 9 GLOBAL BLAU SYNDROME MARKET: VENDOR SHARE ANALYSIS 73

FIGURE 10 GLOBAL BLAU SYNDROME MARKET: SEGMENTATION 76

FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 77

FIGURE 12 HIGH ADOPTION OF BIOLOGICAL THERAPIES AND HIGH DEMAND OF DISEASE SPECIFIC TREATMENT IS DRIVING THE GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 78

FIGURE 13 TREATMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BLAU SYNDROME MARKET IN 2020 & 2027 78

FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET IN GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 79

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF GLOBAL BLAU SYNDROME MARKET 83

FIGURE 16 GLOBAL BLAU SYNDROME MARKET: BY TYPE, 2019 95

FIGURE 17 GLOBAL BLAU SYNDROME MARKET: BY TYPE, 2019-2027 (USD THOUSAND) 96

FIGURE 18 GLOBAL BLAU SYNDROME MARKET: BY TYPE, CAGR (2020-2027) 96

FIGURE 19 GLOBAL BLAU SYNDROME MARKET: BY TYPE, LIFELINE CURVE 97

FIGURE 20 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019 107

FIGURE 21 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019-2027 (USD THOUSAND) 108

FIGURE 22 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027) 108

FIGURE 23 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE 109

FIGURE 24 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019 114

FIGURE 25 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD THOUSAND) 115

FIGURE 26 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027) 115

FIGURE 27 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 116

FIGURE 28 GLOBAL BLAU SYNDROME MARKET: BY END USER, 2019 123

FIGURE 29 GLOBAL BLAU SYNDROME MARKET: BY END USER, 2019-2027 (USD THOUSAND) 124

FIGURE 30 GLOBAL BLAU SYNDROME MARKET: BY END USER, CAGR (2020-2027) 124

FIGURE 31 GLOBAL BLAU SYNDROME MARKET: BY END USER, LIFELINE CURVE 125

FIGURE 32 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019 130

FIGURE 33 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND) 131

FIGURE 34 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 131

FIGURE 35 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 132

FIGURE 36 GLOBAL BLAU SYNDROME MARKET: SNAPSHOT (2019) 139

FIGURE 37 GLOBAL BLAU SYNDROME MARKET: BY REGION (2019) 140

FIGURE 38 GLOBAL BLAU SYNDROME MARKET: BY REGION (2020 & 2027) 140

FIGURE 39 GLOBAL BLAU SYNDROME MARKET: BY REGION (2019 & 2027) 141

FIGURE 40 GLOBAL BLAU SYNDROME MARKET: BY TYPE (2020-2027) 141

FIGURE 41 NORTH AMERICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 143

FIGURE 42 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 144

FIGURE 43 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 144

FIGURE 44 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 145

FIGURE 45 NORTH AMERICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 145

FIGURE 46 EUROPE BLAU SYNDROME MARKET: SNAPSHOT (2019) 167

FIGURE 47 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019) 168

FIGURE 48 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 168

FIGURE 49 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 169

FIGURE 50 EUROPE BLAU SYNDROME MARKET: BY TYPE (2020-2027) 169

FIGURE 51 ASIA PACIFIC BLAU SYNDROME MARKET: SNAPSHOT (2019) 254

FIGURE 52 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2019) 255

FIGURE 53 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 255

FIGURE 54 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 256

FIGURE 55 ASIA PACIFIC BLAU SYNDROME MARKET: BY TYPE (2020-2027) 256

FIGURE 56 SOUTH AMERICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 324

FIGURE 57 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 325

FIGURE 58 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 325

FIGURE 59 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 326

FIGURE 60 SOUTH AMERICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 326

FIGURE 61 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 350

FIGURE 62 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 351

FIGURE 63 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 351

FIGURE 64 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 352

FIGURE 65 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 352

FIGURE 66 GLOBAL BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 392

FIGURE 67 NORTH AMERICA BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 393

FIGURE 68 EUROPE BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 394

FIGURE 69 ASIA-PACIFIC BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 395

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Novartis AG

Pfizer Inc.

AbbVie Inc.

Amgen Inc.

Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)

Mylan N.V.

Hikma Pharmaceuticals PLC

Teva Pharmaceutical U.S.A Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)

Fulgent Genetics Inc.

Invitae Corporation

Swedish Orphan Biovitrum AB

Alkem Labs

Accord Healthcare

F. Hoffmann-La Roche Ltd

Zydus Pharmaceuticals (USA) Inc. (a subsidiary of Zydus cadila)

Amneal Pharmaceuticals LLC

Salix Pharmaceuticals (a subsidiary of Bausch Health Companies Inc.)

Centogene AG

Oncodesign